US downturn fails to halt Dantec's progress:
This article was originally published in Clinica
Dantec Medical (Denmark) saw sales increase 9% in 1994 to DKr 198 million ($37 million), while pre-tax profits were DKr 11.6 million, compared with a loss of DKr 12 million in 1993. Some 97% of overall sales were exported, according to the annual report of Incentive, Dantec's parent company. Dantec, which claims to lead the world urology market, suffered a decline in US business during 1994 as a result of continued recession and the delay in FDA approval of the company's Keypoint EMG system. Dantec says it expects approval to be granted during 1995. This downturn was, however, more than offset by success in other markets, particularly Germany, Japan and China.
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.